Henrik Zetterberg, MD, PhD, describes the core CSF biomarkers used in the diagnosis of Alzheimer’s disease (including tau and Aβ), and how the use of CSF biomarker ratios are superior to single biomarkers, for differential diagnosis across dementia etiologies. He also discusses emerging fluid biomarkers, such as neurofilament light chain and plasma biomarkers. He examines the use and results of fluid biomarker testing in the patient case study. James Leverenz, MD, then describes the role of imaging biomarkers, specifically magnetic resonance imaging (MRI), in the diagnosis of the patient in the case study.
Disclosure: All panelists received honoraria from Biogen for participation in this symposium.
Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.